The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Open accessAbstract
Blockade of PD-L1 expression on tumor cells via anti–PD-L1 monoclonal antibody (mAb) has shown great promise for successful cancer treatment by overcoming T-cell exhaustion; however, the function of PD-L1 on natural killer (NK) cells and the effects of anti–PD-L1 mAb on PD-L1+ NK cells remain unknown. Moreover, patients with PD-L1− tumors can respond favorably to anti–PD-L1 mAb therapy for unclear reasons. Here, we show that some tumors can induce PD-L1 on NK cells via AKT signaling, resulting in enhanced NK-cell function and preventing cell exhaustion. Anti–PD-L1 mAb directly acts on PD-L1+ NK cells against PD-L1− tumors via a p38 pathway. Combination therapy with anti–PD-L1 mAb and NK cell–activating cytokines significantly improves the therapeutic efficacy of human NK cells against PD-L1− human leukemia when compared with monotherapy. Our discovery of a PD-1–independent mechanism of antitumor efficacy via the activation of PD-L1+ NK cells with anti–PD-L1 mAb offers new insights into NK-cell activation and provides a potential explanation as to why some patients lacking PD-L1 expression on tumor cells still respond to anti–PD-L1 mAb therapy. Significance: Targeting PD-L1 expressed on PD-L1+ tumors with anti–PD-L1 mAb successfully overcomes T-cell exhaustion to control cancer, yet patients with PD-L1− tumors can respond to anti–PD-L1 mAb. Here, we show that anti–PD-L1 mAb activates PD-L1+ NK cells to control growth of PD-L1− tumors in vivo, and does so independent of PD-1. This article is highlighted in the In This Issue feature, p. 1325
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 3×
“In addition, anti–PD-L1 mAb therapy can also show an unexplained clinical response in the absence of PD-L1 expression on tumor cells (8, 9).”
BackgroundResultNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Self-citationT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“We and others have previously shown that PD-1 expression on NK cells results in a negative regulatory event upon engagement with its ligand (44–46), as is well known in T cells (40, 47).”
BackgroundAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J. M., & Altfeld, M. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,410
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 2×
“We and others have previously shown that PD-1 expression on NK cells results in a negative regulatory event upon engagement with its ligand (44–46), as is well known in T cells (40, 47).”
Backgroundgp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Self-citationBlank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
The Transcription Factors T-bet and Eomes Control Key Checkpoints of Natural Killer Cell Maturation
Gordon, S. M., Chaix, J., Rupp, L. J., Wu, J., Madera, S., Sun, J. C., Lindsten, T., & Reiner, S. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.11.016 · Cited by 731
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30231-0 · Cited by 509
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
Cutting Edge: Priming of NK Cells by IL-18
Chaix, J., Tessmer, M. S., Hoebe, K., Fuséri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1627 · Cited by 374
NFAT proteins: emerging roles in cancer progression
Mancini, M., & Toker, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2735 · Cited by 371
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Hartley, G. P., Chow, L., Ammons, D. T., Wheat, W. H., & Dow, S. W. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0537 · Cited by 351
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Yu, J., Wei, M., Becknell, B., Trotta, R., Liu, S., Boyd, Z., Jaung, M. S., Blaser, B. W., Sun, J., Benson, D. M., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.016 · Cited by 279
Self-citationThe IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
Trotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
Self-citationTranscription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function
Deng, Y., Kerdiles, Y., Chu, J., Yuan, S., Wang, Y., Chen, X., Mao, H., Zhang, L., Zhang, J., Hughes, T., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.006 · Cited by 179
Self-citationBerthon, C., Driss, V., Liu, J., Kuranda, K., Leleu, X., Jouy, N., Hetuin, D., & Quesnel, B. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0909-y · Cited by 167
Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis
Zhou, J., Peng, H., Li, K., Qu, K., Wang, B., Wu, Y., Ye, L., Dong, Z., Wei, H., Sun, R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.024 · Cited by 157
DNAM-1 controls NK cell activation via an ITT-like motif
Zhang, Z., Wu, N., Lü, Y., Davidson, D., Colonna, M., & Veillette, A. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150792 · Cited by 140
Stabilization of IFN-γ mRNA by MAPK p38 in IL-12– and IL-18–stimulated human NK cells
Mavropoulos, Α., Sully, G., Cope, A. P., & Clark, A. R. (2004) · Blood · doi:10.1182/blood-2004-07-2782 · Cited by 139
Weinstock, C., Khozin, S., Suzman, D. L., Zhang, L., Tang, S. W., Wahby, S., Goldberg, K. B., Kim, G., & Pazdur, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0540 · Cited by 139
NK cells gain higher IFN ‐γ competence during terminal differentiation
Luetke-Eversloh, M. V., Cicek, B. B., Siracusa, F., Thom, J. T., Hamann, A., Frischbutter, S., Baumgrass, R., Chang, H., Thiel, A., Dong, J., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201344072 · Cited by 138
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 135
Tumour MHC class I downregulation and immunotherapy (Review)
Bubenik, J. (2003) · Oncology Reports · doi:10.3892/or.10.6.2005 · Cited by 133
Beider, K., Nagler, A., Wald, O., Franitza, S., Dagan‐Berger, M., Wald, H., Giladi, H., Brocke, S., Hanna, J. H., Mandelboim, O., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3293 · Cited by 124
Gupta, H. B., Clark, C. A., Yuan, B., Sareddy, G. R., Pandeswara, S., Padron, A. S., Hurez, V. J., Conejo-Garcia, J. R., Vadlamudi, R. K., Li, R., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.30 · Cited by 122
Wang, Y., Zhang, Y., Yi, P., Dong, W., Nalin, A. P., Zhang, J., Zhu, Z. G., Chen, L., Benson, D. M., Mundy-Bosse, B. L., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0265-1 · Cited by 121
Self-citationCutting Edge: Stage-Specific Requirement of IL-18 for Antiviral NK Cell Expansion
Madera, S., & Sun, J. C.-Y. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402001 · Cited by 116
Iraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Araya, R. E., Ziblat, A., Domaica, C. I., Sierra, J. M., Núñez, S. Y., Secchiari, F., Gajewski, T. F., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502291 · Cited by 107
Lenzi, R., Edwards, R. P., June, C. H., Seiden, M. V., Garcia, M. E., Rosenblum, M. G., & Freedman, R. S. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-66 · Cited by 93
Pérez‐Martínez, A., Fernández, L., Valentín, J., Martínez-Romera, I., Corral, M. D., Ramírez, M. R., Abad, L., Santamaría, S., González‐Vicent, M., Sirvent, S. I., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.07.011 · Cited by 80
Natural Killer Cells in Innate Immunity and Cancer
Becknell, B., & Caligiuri, M. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318182de23 · Cited by 56
Self-citationFaiena, I., Cummings, A. L., Crosetti, A. M., Pantuck, A. J., Chamie, K., & Drakaki, A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s141491 · Cited by 53
Atezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 49
Liu, X., Wu, X., Cao, S., Harrington, S. M., Yin, P., Mansfield, A. S., & Dong, H. (2016) · Scientific Reports · doi:10.1038/srep36722 · Cited by 43
Self-citationVey, N., Dumas, P., Récher, C., Gastaud, L., Lioure, B., Bulabois, C., Pautas, C., Marolleau, J., Leprêtre, S., Raffoux, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.889.889 · Cited by 40
Rihawi, K., Gelsomino, F., Sperandi, F., Melotti, B., Fiorentino, M., Casolari, L., & Ardizzoni, A. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817725486 · Cited by 30
Robertson, M. J., Stamatkin, C. W., Pelloso, D., Weisenbach, J., Prasad, N. K., & Safa, A. R. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000220 · Cited by 17
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Self-citation
Metadata
- Authors
- Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., & Yu, J.
- Venue
- Cancer Discovery
- Published
- 2019-10-01
- Volume
- 9
- Issue
- 10
- Pages
- 1422-1437
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2963671594
- Cited by
- 302
- References
- 65
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.